Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment

Journal of Clinical Pharmacy and Therapeutics

Volumn 34, Issue 3, 2009, Pages 267-276

  Derosa, G ^a   D'Angelo, A ^a   Franzetti, I G ^b   Ragonesi, P D ^c   Gadaleta, G ^d   Scalise, F ^e   Ciccarelli, L ^f   Piccinni, M N ^g   Cicero, A F G ^h  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

^c SAN CARLO BORROMEO HOSPITAL   (Italy)

^d Civic Hospital   (Italy)

^e Policlinico di Monza   (Italy)

^f RSA Don Leone Porta   (Italy)

^g Fondazione Ospedale Della Caritá   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Combined hyperlipidemia; Ezetimibe; Poligenic hypercholesterolemia; Simvastatin; Type 2 diabetes mellitus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC ACID DERIVATIVE; OMEGA 3 FATTY ACID; ORAL ANTIDIABETIC AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIABETIC PATIENT; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PREVALENCE; RHABDOMYOLYSIS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; MALE; MIDDLE AGED; PREVALENCE; SIMVASTATIN; TRIGLYCERIDES;

EID: 65549116534     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.01004.x     Document Type: Article

References (27)

1. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK (2006) Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine, 166, 2307 2313.
2. Smith SC Jr., Allen J, Blair SN et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation, 113, 2363 2372. (Pubitemid 43947981)
3. Tenenbaum A, Fisman EZ, Motro M, Adler Y (2006) Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovascular Diabetology, 5, 20 28. (Pubitemid 44524381)
4. Guthrie RM (2006) Rising to the challenge of treating high-risk patients. The American Journal of Managed Care, 12, S318 S324. (Pubitemid 44683779)
5. Stone NJ, Bilek S, Rosenbaum S (2005) Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. The American Journal of Cardiology, 96, 53E 59E. (Pubitemid 41140371)
6. Di Martino M, Esposti LD, Filigheddu F et al. (2007) Use of antihypertensive and lipid-lowering drugs: the management of cardiovascular risk in clinical practice. Journal of Human Hypertension, 21, 53 59.
7. Malik S, Lopez V, Chen R, Wu W, Wong ND (2007) Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Research and Clinical Practice, 77, 126 133. (Pubitemid 46590472)
8. Cziraky MJ, Willey VJ, McKenney JM et al. (2006) Statin safety: an assessment using an administrative claims database. The American Journal of Cardiology, 97, 61C 68C.
9. Daskalopoulou SS, Mikhailidis DP (2006) Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Current Medical Research and Opinion, 22, 511 528.
10. Gotto AM Jr., Amrenco P, Assman G et al. (2003) The ILIB lipid handbook for clinical practice: dyslipidemia and coronary heart disease, 3rd edn. New York : International Lipid Information Bureau.
11. Bunn HF, Gabbay KH, Gallop PM (1978) The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science, 200, 21 27. (Pubitemid 8302924)
12. European Diabetes Policy Group 1999 (1999) A desktop guide to type 2 diabetes mellitus. Diabetic Medicine, 16, 716 730. (Pubitemid 29459269)
13. Klose S, Borner K (1978) Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. Journal of Clinical Chemistry and Clinical Biochemistry, 15, 121 130.
14. Wahlefeld AW (1974) Triglycerides determination after enzymatic hydrolysis. In : Bergmeyer HU, ed. Methods of enzymatic analysis, 2nd English edn. New York : Academic Press, 18 31.
15. Havel RJ, Eder HA, Bragdon JH (1955) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation, 34, 1345 1353.
16. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499 502.
17. Winer BJ (1971) Statistical principles in experimental design, 2nd edn. New York : McGraw-Hill.
18. Poluzzi E, Strahinja P, Vaccheri A et al. (2007) Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. British Journal of Clinical Pharmacology, 63, 346 355. (Pubitemid 46257082)
19. McKenney JM (2006) An assessment of statin safety. The American Journal of Managed Care, 12, S310 S317. (Pubitemid 44683778)
20. Anfossi G, Massucco P, Bonomo K, Trovati M (2004) Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutrition, Metabolism, and Cardiovascular Disease, 14, 215 224. (Pubitemid 39462927)
21. Vladutiu GD, Simmons Z, Isackson PJ et al. (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle and Nerve, 34, 153 162. (Pubitemid 44167798)
22. Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM (2006) Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Current Medical Research and Opinion, 22, 2041 2053. (Pubitemid 44663409)
23. Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B (2004) Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Current Medical Research and Opinion, 20, 1437 1445. (Pubitemid 39361347)
24. Goldberg RB, Guyton JR, Mazzone T et al. (2006) Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clinic Proceedings, 81, 1579 1588.
25. Weffald LA, Flach LA (2007) Myopathy associated with atorvastatin- ezetimibe combination therapy. Pharmacotherapy, 27, 309 311. (Pubitemid 46214593)
26. Hildemann SK, Barho C, Karmann B, Darius H, Bestehorn K (2007) Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Current Medical Research and Opinion, 23, 713 719. (Pubitemid 46631474)
27. Drazen JM, D'Agostino RB, Ware JH, Morrisey S, Curfman GD (2008) Ezetimibe and cancer - an uncertain association. New England Jurnal of Medicine, 359, 1398 1399.